Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05026645 Enrolling by invitation - Clinical trials for Acute Respiratory Distress Syndrome

The Medical Management in Patients Exposed to Weapons of Mass Destruction

CBRNEObs
Start date: October 1, 2020
Phase:
Study type: Observational

Observation study measuring medical response in contaminated environment.

NCT ID: NCT05020418 Enrolling by invitation - Clinical trials for Antibiotics Causing Adverse Effects in Therapeutic Use

De-Implementation of Inappropriate Antimicrobial Use After Cardiac Device Procedures

CIED
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

This project will use automated audit and feedback to improve compliance with antimicrobial prophylaxis guidelines for CIED procedures that we anticipate will translate into better outcomes for our patients. A multi-faceted implementation bundle to promote de-implementation of guideline discordant care will be tested at three intervention sites. Materials and tools will then be disseminated throughout the VA healthcare system if the intervention is found to be effective.

NCT ID: NCT05013710 Enrolling by invitation - Reproductive Health Clinical Trials

Evaluating the Mobile Clinic Model as a Means of Increasing Access to Reproductive and Sexual Health

MHCE
Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

The mobile health clinic evaluation study examines the impact of mobile health clinics on access reproductive and sexual healthcare services in underserved communities. Multiple mobile clinics operating throughout the U.S. are participating by implementing the same evaluation plan for their programs and contributing de-identified data into a shared database. This allows the investigators to both determine the impact of individual programs and to compare and contrast their impact across different programs, states, population densities (rural, urban, suburban), and populations.

NCT ID: NCT04997850 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma Non-resectable

The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma

Start date: May 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

We adopted the prospective cohort study to compare the safety and efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody in the treatment of advanced unresectable liver cancer.The purposes of our study include:1. Primary objective: To compare the safety and efficacy of TACE combined with Lenvatinib and PD-1 antibody versus TACE alone in the conversion-resection of patients with advanced unresectable hepatocellular carcinoma.2. Secondary objective: To compare the long-term outcome of TACE combined with Lenvatinib and PD-1 antibody versus TACE alone for patients with advanced unresectable hepatocellular carcinoma.

NCT ID: NCT04984447 Enrolling by invitation - Clinical trials for Environmental Enteric Dysfunction

OCT Guided Trans Nasal Imaging of the Small Intestine in Adults

Start date: September 22, 2017
Phase: N/A
Study type: Interventional

The investigators are seeking healthy adult volunteers 18-60 years and healthy pregnant women in their 2nd trimester of pregnancy for a research study to assess a new imaging device. The Tearney Laboratory at the Wellman Center for Photomedicine at Massachusetts General Hospital is developing high-resolution imaging devices that can be used to improve diagnostics in gastrointestinal diseases.

NCT ID: NCT04979650 Enrolling by invitation - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis

Start date: May 22, 2021
Phase: Phase 2
Study type: Interventional

to determine the rate of asymptomatic gadolinium-enhancing lesions conversion to the non-enhancing black hole (neBHs) with or without corticosteroid pulse therapy in patients with RRMS, and to analyze if treatment of asymptomatic gadolinium enhancement lesions has any effect on the expanded disability status scale. The study is performed in the MS clinic of Bu Ali Sina Hospital in Sari and Mazandaran University of Medical Sciences. 104 recurrent MS patients are admitted based on the admission criteria. They are divided into two groups of intervention and control based on a simple randomization block. The intervention group received 1 gram of methylprednisolone in 500 ccs of normal saline for 5 days and the control group received only 500 ccs of serum. After 6 months, a new MRI is taken from the patients and the possibility of asymptomatic active plaque conversion with or without intervention is compared in the two groups, as well as the amount of EDSS in the two groups. They do not know whether the patient is in the control group or the intervention.

NCT ID: NCT04974320 Enrolling by invitation - Prognosis Clinical Trials

Rapid Identification of MINOCA Based on Novel Biomarkers

Start date: June 5, 2021
Phase:
Study type: Observational

Among the patients diagnosed as acute myocardial infarction by coronary angiography, 5%-25% of the patients did not find coronary artery obstructive lesions. These patients do not need PCI. The discovery and verification of clinical protocols for accurate identification of myocardial infarction in the absence of obstructive coronary artery disease(MINOCA)is a major issue that needs to be addressed.Novel biomarkers like grow stimulation expressed gene 2(ST2)can indicate the degree of coronary artery obstruction, copeptin is a biomarker of cardiac emergency state. No clinical studies have been conducted to evaluate whether the novel biomarkers combination regimen can diagnose or exclude MINOCA. Our research aims to establish and validate a model for the recognition of MINOCA based on novel biomarkers (ST2, copeptin) and to evaluate the prognostic value of novel biomarkers among patients with acute chest pain.

NCT ID: NCT04970303 Enrolling by invitation - Clinical trials for Attention Deficit Hyperactivity Disorder

Endocrine Disrupting Chemicals and Hormones in ADHD

ADHD
Start date: July 12, 2019
Phase:
Study type: Observational

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Growth hormone and thyroid function are associated with both physical and neurocognitive development. Endocrine disrupting chemicals (EDCs) could disturb the normal function of endocrine systems, and further link to the pathophysiology of ADHD. In addition, whether methylphenidate for treating ADHD influences growth hormone and thyroid function of patients remains unclear.

NCT ID: NCT04970238 Enrolling by invitation - Heart Failure Clinical Trials

Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction

Start date: October 2021
Phase: Phase 4
Study type: Interventional

Reperfusion therapy for acute ST segment elevation myocardial infarction (STEMI) can significantly reduce mortality, but patients may still have heart failure and adverse cardiovascular events due to massive myocardial loss. About 20% of patients present with acute heart failure (AHF) at admission, It is the most important cause of hospital death in acute myocardial infarction. Because of the large necrotic area of acute anterior myocardial infarction, heart failure still occurs in a considerable number of patients even after revascularization (PCI). Myocardial protection of ischemic myocardium is a hot topic in clinical research. Both ESC and Chinese heart failure guidelines recommend levosimendan for the treatment of acute decompensated heart failure. A large number of studies have proved that levosimendan can significantly reduce myocardial injury and improve cardiac function in patients with acute STEMI complicated with left ventricular dysfunction and cardiogenic shock compared with placebo. Basic research has confirmed that levosimendan can reduce the myocardial infarction area after acute coronary occlusion, improve the left ventricular function, and exert the effects of anti myocardial ischemia, myocardial injury, myocardial fibrosis, ventricular remodeling and anti apoptosis. However, there is still a lack of early preventive application of levosimendan in acute anterior myocardial infarction after PCI to improve ventricular remodeling and reduce the incidence of heart failure. The purpose of this study was to investigate the effect of early prophylactic levosimendan on left ventricular remodeling, ischemic myocardial protection and the development of heart failure in patients with acute anterior myocardial infarction after PCI.

NCT ID: NCT04956536 Enrolling by invitation - Clinical trials for Anterior Cruciate Ligament Injuries

Anterior Tibial Subluxation in the Setting of ACL-injury and After ACL Reconstruction

Start date: December 1, 2020
Phase:
Study type: Observational

To identify the related factors for anterior tibial subluxation (ATS) on anterior cruciate ligament-injured MRI images.